Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids

Journal of Pathology

Volumn 187, Issue 3, 1999, Pages 321-325

  Cunningham, Rodat T ^a   Pogue, Kathy M ^a   Curry, William J ^a   Johnston, Colin F ^a,c   Sloan, James M ^b   Buchanan, Keith D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c Institute of Clinical Sciences B   (United Kingdom)

Author keywords

Carcinoid tumours; Chromogranin A; Diagnosis; Neuroendocrine tumours

Indexed keywords

ANTIBODY; ANTISERUM; CHROMOGRANIN A; PEPTIDE; UNCLASSIFIED DRUG; VASOSTATIN I;

ARTICLE; CARCINOID; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; ILEUM DISEASE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG DISEASE; PRIORITY JOURNAL;

CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; DIAGNOSIS, DIFFERENTIAL; FLUORESCENT ANTIBODY TECHNIQUE; FLUSHING; HUMANS; ILEAL NEOPLASMS; LUNG NEOPLASMS; PEPTIDE FRAGMENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032896271     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199902)187:3<321::AID-PATH258>3.0.CO;2-9     Document Type: Article

References (16)

1. Hendy GN, Bevan S, Mattei MG, Mouland AJ. Chromogranin A. Clin Invest Med 1995; 18: 47-65.
2. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic polypeptide that inhibits insulin secretion. Nature 1986; 324: 476-478.
3. 347 419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 1993; 133: 461-466.
4. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regulatory Peptides 1992; 41: 9-18.
5. O'Connor DT, Takiyyuddin MA, Cervenka JH, et al. Circulating chromogranin A as a diagnostic tool in clinical chemistry. Acta Histochem Suppl 1990; XXXVII: S27-S33.
6. Cunningham RT, Johnston CF, Irvine GB, McIlrath EM, McNeill A, Buchanan KD. Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intrahepatic arterial streptozotocin and floxuridine. Clin Chim Acta 1990; 189: 275-286.
7. Cunningham RT, Curry WJ, Johnston CF, Buchanan KD. Development of a radioimmunoassay to a fragment of vasostatin II. Bioc Soc Trans 1996; 24: 304S.
8. Johnston CF, O'Neill AB, O'Hare MMT, Buchanan KD. Neuroendocrine cells within colorectal tumours induced by dimethylhydrazine - an immunohistochemical study. Cell Tissue Res 1986; 246: 205-210.
9. Wang DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 1995; 175: 397-401.
10. 2+-induced conformational change and aggregation of chromogranin A. J Biol Chem 1990; 265: 14414-14421.
11. Kema IP, Devries EGE, Sloof MJH, Biesma B, Muskiet FAJ. Serotonin, catecholamines, histamine and other metabolites in urine, platelets and tumor tissue of patients with carcinoid tumors. Clin Chem 1994; 40: 86-95.
12. Moertel CG, Johnston CM, McKusick MA, et al. The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 1994; 120: 302-309.
13. Conlon JM, Deacon CF, Richter G, Stockman F, Creutzfeldt W. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987; 22: 97-105.
14. Gronstad KO, Nilsson O, Hedman I, Skolnik G, Dahlstrom A, Ahlman H. On the mode of action of the pentagastrin test in the carcinoid syndrome. Scand J Gastroenterol 1985; 20: 508-511.
15. Nilsson O, Gronstad KO, Goldstein M, Skolnik G, Dahlstrom A, Ahlman H. Adrenergic control of serotonin release from a midgut carcinoid tumour. Int J Cancer 1985; 36: 307-312.
16. Capella C, Gabriella M, Polak JM, Buffa R, Solcia E. Ultrastructural and histological study of 11 bronchial carcinoids. Virchows Archiv A 1979; 381: 313-319.